{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,25]],"date-time":"2026-07-25T09:14:50Z","timestamp":1784970890894,"version":"3.55.0"},"reference-count":133,"publisher":"Informa UK Limited","issue":"11","content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/14737140.2023.2267760","type":"journal-article","created":{"date-parts":[[2023,10,9]],"date-time":"2023-10-09T17:13:19Z","timestamp":1696871599000},"page":"1193-1204","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Shedding light on the side effects of immunotherapies used for leukemia: an updated review of the literature"],"prefix":"10.1080","volume":"23","author":[{"given":"Kimia","family":"Kazemzadeh","sequence":"first","affiliation":[{"name":"Students\u2019 Scientific Research Center, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Network of Neurosurgery and Artificial Intelligence (NONAI), Universal Scientific Education and Research Network (USERN), Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sadra","family":"Behrouzieh","sequence":"additional","affiliation":[{"name":"Cancer Immunology Project (CIP), Universal Scientific Education and Research Network (USERN), Tehran, Iran"},{"name":"School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3836-1827","authenticated-orcid":false,"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[{"name":"Network of Neurosurgery and Artificial Intelligence (NONAI), Universal Scientific Education and Research Network (USERN), Tehran, Iran"},{"name":"Research Center for Immunodeficiencies, Pediatrics Center of Excellence, Children\u2019s Medical Center, Tehran University of Medical Sciences, Tehran, Iran"},{"name":"Department of Immunology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,9]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a034819"},{"key":"e_1_3_4_3_1","article-title":"Leukemia: symptoms and causes","author":"mayoclinic","year":"2021","unstructured":"mayoclinic. Leukemia: symptoms and causes. Mayo Clinic. 2021 [cited 2022 Dec 12].Available from: https:\/\/www.mayoclinic.org\/disease-conditions\/leukemia\/symptoms-causes\/syc-20374373","journal-title":"Mayo Clinic"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/aqz093"},{"key":"e_1_3_4_5_1","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.639479"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/1612702"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21708"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.3390\/genes11080845"},{"key":"e_1_3_4_10_1","volume-title":"What makes immunotherapy for leukemia a promising treatment","author":"Huang A.","year":"2021","unstructured":"Huang A. What makes immunotherapy for leukemia a promising treatment. Cancer Research Institute; 2021 [cited 2022 Dec 12]. Available from:https:\/\/www.cancerresearch.org\/cancer-types\/leukemia"},{"key":"e_1_3_4_11_1","unstructured":"Villines Z. Immunotherapy for leukemia: types success rate and more: medical news Today 2021. [cited2022 Dec 12]. Available from: https:\/\/www.medicalnewstoday.com\/articles\/immunotherapy-for-leukemia"},{"key":"e_1_3_4_12_1","unstructured":"Institute nc. immunotherapy to treat cancer: national cancer institute; 2019 [Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy."},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.aay4458"},{"key":"e_1_3_4_14_1","unstructured":"Huang A What makes immunotherapy for leukemia a promising treatment? : CRI; [Available from: https:\/\/www.cancerresearch.org\/cancer-types\/leukemia."},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1038\/nri3820"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/13696998.2019.1582059"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaa8172"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-94-009-1844-3_6"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2016.02.024"},{"key":"e_1_3_4_20_1","unstructured":"Society AC. Monoclonal antibodies for chronic lymphocytic Leukemia: American Cancer Society; 2019 [Available from: https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/treating\/monoclonal-antibodies.html."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-008-0260-6"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2002.20.5.1215"},{"key":"e_1_3_4_23_1","unstructured":"Institute D-F CAR T-Cell therapy for leukemia: dana-farber cancer Institute [Available from: https:\/\/www.dana-farber.org\/cellular-therapies-program\/car-t-cell-therapy\/car-t-cell-therapy-for-leukemia\/."},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccl.2019.07.008"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.882531"},{"key":"e_1_3_4_26_1","unstructured":"Institute NC. Immune checkpoint inhibitors: National Cancer Institute; 2022 [Available from: https:\/\/www.cancer.gov\/about-cancer\/treatment\/types\/immunotherapy\/checkpoint-inhibitors."},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2018.02.037"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.192.7.1027"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/1759-7714.13275"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-017-0336-3"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdermsci.2016.12.019"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e318247a4e7"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.14043"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/14712598.2018.1425389"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.3949\/ccjm.87a.19119"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"e_1_3_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.16873"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1139"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/B978-0-12-407190-2.00007-1"},{"key":"e_1_3_4_40_1","doi-asserted-by":"publisher","DOI":"10.12788\/jhm.2925"},{"key":"e_1_3_4_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.24"},{"key":"e_1_3_4_42_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"e_1_3_4_43_1","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjv227"},{"key":"e_1_3_4_44_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-014-1687-9"},{"key":"e_1_3_4_45_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-420596"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1038\/cti.2014.11"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1186\/2052-8426-2-25"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw558"},{"key":"e_1_3_4_50_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaneurol.2017.1912"},{"key":"e_1_3_4_51_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2018-0359"},{"key":"e_1_3_4_53_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2016.02.003"},{"key":"e_1_3_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2017.05.003"},{"key":"e_1_3_4_55_1","doi-asserted-by":"publisher","DOI":"10.2147\/CMAR.S136818"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000144"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2017.04.031"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11030305"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdv383"},{"key":"e_1_3_4_60_1","doi-asserted-by":"publisher","DOI":"10.1159\/000161122"},{"issue":"4","key":"e_1_3_4_61_1","first-page":"1355","article-title":"Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor","volume":"32","author":"Wilgenhof S","year":"2012","unstructured":"Wilgenhof S, Morlion V, Seghers AC, et al. Sarcoidosis in a patient with metastatic melanoma sequentially treated with anti-CTLA-4 monoclonal antibody and selective BRAF inhibitor. Anticancer Res. 2012;32(4):1355\u20131359.","journal-title":"Anticancer Res"},{"key":"e_1_3_4_62_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.37.9693"},{"key":"e_1_3_4_63_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-1467"},{"key":"e_1_3_4_64_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.3298"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaophthalmol.2018.0920"},{"key":"e_1_3_4_66_1","unstructured":"Clandos R Ophthalmologists link immunotherapy with a serious eye condition: Michigan Health Lab; 2018 [Available from: https:\/\/labblog.uofmhealth.org\/rounds\/ophthalmologists-link-immunotherapy-a-serious-eye-condition."},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1080\/09273948.2019.1583347"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100276"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw696"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.1641"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.1200\/JGO.17.00019"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2017.00049"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.60.0379"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000186"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11102-015-0671-4"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.cji.0000178913.41256.06"},{"key":"e_1_3_4_77_1","volume-title":"Endocrine society\u2019s 97th annual meeting and expo","author":"MJP RD","year":"2015","unstructured":"MJP RD, Cabanillas M, Shah K, et al. Hypophysitis in the age of cancer immunotherapy: experience in alarge cancer center. In: Waguespack S, editor. Endocrine society\u2019s 97th annual meeting and expo. San Diego: CA; 2015."},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2012-4075"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrendo.2016.205"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.7326\/M15-3016"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40842-018-0073-4"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-017-0300-z"},{"key":"e_1_3_4_83_1","unstructured":"Yervoy. summary of product characteristics: ema.Europa.eu; 2011 [Available from: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/yervoy-epar-product-information_en.pdf."},{"key":"e_1_3_4_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1200694"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504627"},{"key":"e_1_3_4_86_1","doi-asserted-by":"publisher","DOI":"10.1111\/imj.15123"},{"key":"e_1_3_4_87_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41584-018-0074-9"},{"key":"e_1_3_4_88_1","volume-title":"OP0088 immune-related adverse events of cancer immunotherapy\u2013when inflammatory side effects are associated with survival: a single-centre prospective cohort study","author":"Kostine M","year":"2018","unstructured":"Kostine M, Mauric E, Rouxel L, et al. OP0088 immune-related adverse events of cancer immunotherapy\u2013when inflammatory side effects are associated with survival: a single-centre prospective cohort study. BMJ Publishing Group Ltd; 2018."},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2019-000906"},{"key":"e_1_3_4_90_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2018.20"},{"key":"e_1_3_4_91_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1083-8791(00)70002-4"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2016.10.008"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2017-221801"},{"key":"e_1_3_4_94_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.707191"},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199912)62:4<247:AID-AJH9>3.0.CO;2-T"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells10010010"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.2144\/fsoa-2019-0009"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2021-0344"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40800-017-0060-1"},{"key":"e_1_3_4_100_1","unstructured":"institute cr. Immunotherapy For Leukemia Cancer: CRI; https:\/\/www.cancerresearch.org\/cancer-types\/leukemia."},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"key":"e_1_3_4_102_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminoncol.2006.01.027"},{"issue":"9","key":"e_1_3_4_103_1","first-page":"333","article-title":"Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands","volume":"65","author":"Laros-van Gorkom B","year":"2007","unstructured":"Laros-van Gorkom B, Huisman C, Wijermans P, et al. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands. Neth J Med. 2007;65(9):333\u2013338.","journal-title":"Neth J Med"},{"key":"e_1_3_4_104_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.13569"},{"key":"e_1_3_4_105_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2007.09.001"},{"key":"e_1_3_4_106_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.onc.1210364"},{"key":"e_1_3_4_107_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.12862"},{"key":"e_1_3_4_108_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2828"},{"key":"e_1_3_4_109_1","doi-asserted-by":"publisher","DOI":"10.1586\/era.10.223"},{"key":"e_1_3_4_110_1","unstructured":"Medicine nlo. Ofatumumab: NIH; 2020 [Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK548649\/."},{"issue":"7","key":"e_1_3_4_111_1","first-page":"626","article-title":"Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia","volume":"61","author":"\u0160imkovi\u010d M","year":"2015","unstructured":"\u0160imkovi\u010d M, Vod\u00e1rek P, Moty\u010dkov\u00e1 M, et al. Rituximab infusion-related toxicity in patients with chronic lymphocytic leukemia. Vnitr Lek. 2015;61(7\u20138):626\u2013632.","journal-title":"Vnitr Lek"},{"key":"e_1_3_4_112_1","unstructured":"Anwer NR: NIH; 2022 [Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK564374\/."},{"key":"e_1_3_4_113_1","doi-asserted-by":"publisher","DOI":"10.1177\/10600280211026338"},{"issue":"7","key":"e_1_3_4_114_1","first-page":"3636","article-title":"CAR T-Cell therapy associated ocular adverse events reported to the Food and drug administration","volume":"61","author":"Fischer A","year":"2020","unstructured":"Fischer A, Li A. CAR T-Cell therapy associated ocular adverse events reported to the Food and drug administration. Invest Ophthalmol Visual Sci. 2020;61(7):3636\u2013.","journal-title":"Invest Ophthalmol Visual Sci"},{"key":"e_1_3_4_115_1","unstructured":"Society lal. interferon alfa-2a [Available from: https:\/\/www.lls.org\/drug\/interferon-alfa-2a."},{"key":"e_1_3_4_116_1","unstructured":"Society lal. interferon alfa-2b [Available from: https:\/\/www.lls.org\/drug\/interferon-alfa-2b."},{"key":"e_1_3_4_117_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(13)70551-5"},{"key":"e_1_3_4_118_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1709684"},{"key":"e_1_3_4_119_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-02-567453"},{"key":"e_1_3_4_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)61403-3"},{"key":"e_1_3_4_121_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1609783"},{"key":"e_1_3_4_122_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1601202"},{"key":"e_1_3_4_123_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.990"},{"key":"e_1_3_4_124_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385"},{"key":"e_1_3_4_125_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aar6711"},{"key":"e_1_3_4_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chest.2018.08.1048"},{"key":"e_1_3_4_127_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2015.11.016"},{"key":"e_1_3_4_128_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-18-0774"},{"key":"e_1_3_4_129_1","unstructured":"Gresh RC Immunotherapy to treat cancer: KidsHealth; 2019 [Available from: https:\/\/kidshealth.org\/en\/parents\/immunotherapy."},{"key":"e_1_3_4_130_1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0b013e3283350d3e"},{"key":"e_1_3_4_131_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMsa060185"},{"key":"e_1_3_4_132_1","doi-asserted-by":"publisher","DOI":"10.1093\/med\/9780198797210.003.0008"},{"key":"e_1_3_4_133_1","doi-asserted-by":"publisher","DOI":"10.1097\/CCM.0000000000002053"},{"key":"e_1_3_4_134_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-16-0040"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2023.2267760","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T19:17:25Z","timestamp":1727205445000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2023.2267760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,9]]},"references-count":133,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/14737140.2023.2267760"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2023.2267760","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,9]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-06-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-03","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}